Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

211At and 211At-labeled radiopharmaceuticals for targeted alpha therapy

  • Kang, Choong Mo (Division of Applied RI, Korea Institute of Radiological and Medical Sciences) ;
  • Lee, Kyo Chul (Division of Applied RI, Korea Institute of Radiological and Medical Sciences) ;
  • Lee, Yong Jin (Division of Applied RI, Korea Institute of Radiological and Medical Sciences)
  • Received : 2018.12.21
  • Accepted : 2018.12.29
  • Published : 2018.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

$^{211}At$ is an alpha emitting radionuclide, which can be produced using cyclotron with alpha beam. In addition, its strong linear energy transfer and iodine-like chemistry make that $^{211}At$ is one of the most attractive radionuclide in the field of targeted alpha therapy. In this review, production, labeling, and radiopharmaceuticals of $^{211}At$ will be discussed.

Keywords

DHBSB1_2018_v4n2_99_f0001.png 이미지

Figure 1. Decay mode of 211At (EC=electron capture, t1/2=half-life).

DHBSB1_2018_v4n2_99_f0002.png 이미지

Figure 2. Experimental cross-section of the irradiation of 209Bi (8)

DHBSB1_2018_v4n2_99_f0003.png 이미지

Figure 3. Apparatus and reagents for wet extraction (11).

DHBSB1_2018_v4n2_99_f0004.png 이미지

Figure 4. Dry distillation system (13).

DHBSB1_2018_v4n2_99_f0005.png 이미지

Figure 5. STB precursur and scheme for 211At labeling.

DHBSB1_2018_v4n2_99_f0006.png 이미지

Figure 6. Boron cage derivatives for 211At labeling

Table 1. Main production sites of 211At in the world

DHBSB1_2018_v4n2_99_t0001.png 이미지

Table 2. 211At-labled radiopharmaceuticals

DHBSB1_2018_v4n2_99_t0002.png 이미지

References

  1. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and Immunoconjugates. CA Cancer J Clin 2006;56:226-243. https://doi.org/10.3322/canjclin.56.4.226
  2. Makvandi M, Dupis E, Engle JW, Nortier FM, Fassbender ME, Simon S, Birnbaum ER, Atcher RW, John KD, Rixe O, Norenberg JP. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. Target Oncol 2018;13:189-203. https://doi.org/10.1007/s11523-018-0550-9
  3. Milenic DE, Brechbeil MW. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther 2004;3:361-370. https://doi.org/10.4161/cbt.3.4.790
  4. Kang HJ, Lee SS, Byun BH, Kim KM, Lim I, Choi CW, Suh C, Kim WS, Nam SH, Lee SI, Eom HS, Shin DY, Lim SM. Repeated radioimmunotherapy with $^{131}I$-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2013;71:945-953. https://doi.org/10.1007/s00280-013-2087-z
  5. Zalutsky MR, Pruszynski M. Astatine-211: Production and Availability. Curr Radiopharm 2011;4:177-185. https://doi.org/10.2174/1874471011104030177
  6. Harrison J, Leggett R, Lloyd L, Phipps A, Scott B. Polonium-210 as a poison. J Radiol Prot 2007;27:17-40. https://doi.org/10.1088/0952-4746/27/1/001
  7. Kirby HK. Gmelin Handbook of Inorganic Chemistry - Astatine. 8th ed. New York: Springer-Verlag; 1985. p. 95-106.
  8. Guerard F, Gestin JF, Brechbiel MW. Production of [$^{211}At$]-Astatinated Radiopharmaceuticals and Applications in Targeted a-Particle Therapy. Cancer Biother Radiopharm 2013;28:1-20. https://doi.org/10.1089/cbr.2012.1292
  9. Henriksen G, Messelt S, Olsen E, Larsen RH. Optimisation of cyclotron production parameters for the $^{209}Bi({\alpha},\;2n)^{211}At$ reaction related to biomedical use of $^{211}At$. Appl Radiat Isot 2001;54:839-844. https://doi.org/10.1016/S0969-8043(00)00346-8
  10. Lebeda O, Jiran R, Ralis J, Stursa J. A new internal cyclotron target system for production of $^{211}At$ on the cyclotron U-120M. Int J Appl Radiat Isot 2005;63:49-53. https://doi.org/10.1016/j.apradiso.2005.02.006
  11. Schwarz UP, Plascjak P, Beitzel MP, Gansow OA, Eckelman WC, Waldmann TA. Preparation of $^{211}At$-labeled humanized anti-Tac using $^{211}At$ produced in disposable internal and external bismuth targets. Nucl Med Biol 1998;25:89-93. https://doi.org/10.1016/S0969-8051(97)00165-0
  12. Alfarano A, Abbas K, Holzwarth U, Bonardi M, Groppi F, Alfassi Z, Menapace E, Gibson PN. Thick target yield measurement of $^{211}At$ through the nuclear reaction $^{209}Bi({\alpha},2n)$. J Phys Conf Series 2006;41:115-122. https://doi.org/10.1088/1742-6596/41/1/009
  13. Yordanov AT, Pozzi O, Carlin S, Akabani G, Zalutsky MR. Wet harvesting of no-carrier-added $^{211}At$ from an irradiated $^{209}Bi$ target for radiopharmaceutical applications. J Radioanalyt Nucl Chem 2004;262:593-599. https://doi.org/10.1007/s10967-004-0481-z
  14. Champion J, Alliot C, Huclier S, Deniaud D, Asfari Z, Montavon G. Determination of stability constants between complexing agents and At(I) and At(III) species present at ultra-trace concentrations. Inorganica Chimica Acta 2009;362:2654-2661. https://doi.org/10.1016/j.ica.2008.12.005
  15. Lindegren S, Back T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot 2001;55:157-160. https://doi.org/10.1016/S0969-8043(01)00044-6
  16. Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 3: alpha-particle-induced radiolytic effects on the chemical behavior of $^{211}At$. J Nucl Med 2007;48:1190-1206. https://doi.org/10.2967/jnumed.106.038505
  17. Friedman AM, Zalutsky MR, Wung W, Buckinham F, Harper PV Jr. Scherr GH, Wainer B, Hunter RL, Appelman EH, Rothberg RM, Fitch FW, Stuart FP, Simonian SJ. Preparation of a biologically stable and immunogenically competent astatinated protein. Int J Nucl Med Biol 1977;4:219-224. https://doi.org/10.1016/0047-0740(77)90146-2
  18. Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1 : Effects of solvent on the degradation of radiohalogenation precursors by astatine-211 ${\alpha}$-particles. J Nucl Med 2005;46:700-706.
  19. Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 2 : radiolytic effects of $^{211}At$ alpha-particles influence N-succinimidyl 3-$^{211}At$-astatobenzoate synthesis. J Nucl Med 2005;46:1393-1400.
  20. Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for $^{211}At$ labeling at high activities and radiation doses of $^{211}At\;{\alpha}$-particles. Nucl Med Biol 2017;46:43-49. https://doi.org/10.1016/j.nucmedbio.2016.11.009
  21. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Freidman HS, McLendon RE, Wong TZ, Bigner DD. Clinical experience with ${\alpha}$-emitting astatine-211: treatment of recurrent brain tumor patients with $^{211}At$-labeled chimeric 81C6 antitenascin monoclonal antibody 81C6. J Nucl Med 2008;49:30-38.
  22. Wilbur DS, Vessella RL, Stray JE, Goffe DK, Blouke KA, Atcher RW. Preparation and evaluation of para-[$^{211}At$] astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[$^{125}I$]iodobenzoyl labeled A6H F(ab')2. Nucl Med Biol 1993;20:917-927. https://doi.org/10.1016/0969-8051(93)90092-9
  23. Persson, MI, Gedda L, Jensen HJ, Lundqvist H, Malmstrom PU, Tolmachev V. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol Rep 2006;15:673-680.
  24. Visser GWM, Deimer EL, Kaspersen FM. The preparation and stability of $^{211}At$-astato-imidazoles. Int J Appl Rad Isot 1980;31:275-278. https://doi.org/10.1016/0020-708X(80)90033-2
  25. Gdarg PK, Johdn CS, Zalutsky MR. Preparation and preliminary evaluation of 4-[$^{211}At$]astato-N-piperidinoethyl benzamide. Nucl Med Biol 1995;22:467-473. https://doi.org/10.1016/0969-8051(94)00134-6
  26. Ayed T, Pilme J, Teze D, Bassal F, Barbet J, Cherel M, Champion J, Maurice R, Montavon G, Galland N. $^{211}At$-labeled agents for alpha-immunotherapy: On the in vivo stability of astatine-agent bonds. Eur J Med Chem 2016;116:156-164. https://doi.org/10.1016/j.ejmech.2016.03.082
  27. Wilbur DS. Chemical and Radiochemical Considerations in Radiolabeling with ${\alpha}$-Emitting Radionuclides. Curr Radiopharm 2011;4:214-247. https://doi.org/10.2174/1874471011104030214
  28. Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of $^{211}At$-labeled trastuzumab in human breast cancer cell lines: Effect of specific activity and HER2 receptor heterogeneity. Nucl Med Biol 2006;33:333-347. https://doi.org/10.1016/j.nucmedbio.2005.12.006
  29. Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur DS, Balkan ER, Lin Y, Miller BW, Frost SH, Gopal AK, Orozco JJ, Gooley TA, Laird KL, Till BG, Back T, Sandmaier BM, Pagel JM, Press OW. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood 2015;125:2111-2119. https://doi.org/10.1182/blood-2014-11-612770
  30. Cederkrantz E, Andersson H, Bernhardt P, Back T, Hultborn R, Jacobsson L, Jensen H, Lindegren S, Ljungberg M, Magnander T, Palm S, Albertsson P. Absorbed Doses and Risk Estimates of $^{211}At$-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients. Int J Radiat Oncol Biol Phys 2015;93:569-576. https://doi.org/10.1016/j.ijrobp.2015.07.005
  31. Orozco JJ, Back T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides MD, Green DJ, Gopal AK, Press OW, Pagel JM. Anti-CD45 radioimmunotherapy using $^{211}At$ with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood 2013;121:3759-3767. https://doi.org/10.1182/blood-2012-11-467035
  32. Li Y, Hamlin DK, Chyan MK, Wong R, Dorman EF, Emery RC, Woodle DR, Manger RL, Nartea M, Kenoyer AL, Orozco JJ, Green DJ, Press OW, Storb R, Sandmaier BM, Wilbur DS. cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies. PLoS One 2018;13:e0205135 https://doi.org/10.1371/journal.pone.0205135
  33. Vaidyanathan G, Zalutsky MR. 1-(m-[$^{211}At$]astatobenzyl) guanidine: Synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjug Chem 1992;3:499-503. https://doi.org/10.1021/bc00018a006
  34. Vaidyanathan G, Friedman HS, Keir ST, Zalutsky MR. Evaluation of meta-[$^{211}At$]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Nucl Med Biol 1996;23:851-856. https://doi.org/10.1016/0969-8051(96)00115-1
  35. Vaidyanathan G, Affleck, DJ, Alston KL, Zhao XG, Hens M, Hunter DH, Babich J, Zalutsky MR. A kit method for the high level synthesis of [$^{211}At$]MABG. Bioorg Med Chem 2007;15:3430-3436. https://doi.org/10.1016/j.bmc.2007.03.016
  36. Rowe SP, Drzezga A, Neumaier B, Dietlein M, Gorin MA, Zalutsky MR, Pomper MG. Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. J Nucl Med 2016;57:90S-96S. https://doi.org/10.2967/jnumed.115.170175
  37. Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, Brummet M, Chen Y, Choi J, Koumarianou E, Baidoo K, Brechbiel MW, Mease RC, Sgouros G, Zalutsky MR, Pomper MG. (2S)-2-(3-(1-Carboxy-5-(4-$^{211}At$-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted ${\alpha}$-Particle Radiopharmaceutical Therapy. J Nucl Med 2016;57:1569-1575. https://doi.org/10.2967/jnumed.116.174300
  38. Dmitriev OY, Lutsenko S, Muyldermans S. Nanobodies as Probes for Protein Dynamics in Vitro and in Cells. J Biol Chem 2016;291:3767-3775. https://doi.org/10.1074/jbc.R115.679811
  39. Choi J, Vaidyanathan G, Koumarianou, Kang CM, Zalutsky MR. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. Nucl Med Biol 2017;56:10-20.
  40. Kim G, Chun K, Park SH, Kim B. Production of alpha-particle emitting $^{211}At$ using 45 MeV alpha-beam. Phys Med Biol 2014;59:2849-2860. https://doi.org/10.1088/0031-9155/59/11/2849
  41. Crawford JR, Yang H, Kunz P, Wilbur DS, Schaffer P, Ruth TJ. Development of a preclinical $^{211}Rn/^{211}At$ generator system for targeted alpha therapy research with $^{211}At$. Nucl Med Biol 2017;48:31-35. https://doi.org/10.1016/j.nucmedbio.2017.01.011